Read previous post:
Shares of the Theratechnologies fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company's tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Theratechnologies gets top pick status at Echelon Wealth

Echelon Wealth Partners analyst Doug Loe is sticking to his guns on Theratechnologies (TSX:TH). Analysts from Echelon have been rolling...

Close